Trials / Unknown
UnknownNCT00993525
Intravitreal Ranibizumab For Persistent New Vessels In Diabetic Retinopathy(Inipe Study)
INTRAVITREAL RANIBIZUMAB FOR PERSISTENT NEW VESSELS IN DIABETIC RETINOPATHY (INIPE STUDY)
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 22 (estimated)
- Sponsor
- University of Sao Paulo · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the fluorescein angiographic and visual acuity effects of a single intravitreal injection of ranibizumab for the management of persistent new vessels associated with diabetic retinopathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Intravitreal injection of ranibizumab | 0.5 mg at week 0 0.5mg at weeks 12,24,36,48 if fluorescein leakage from active vessels on angiography |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2010-03-01
- Completion
- 2010-03-01
- First posted
- 2009-10-12
- Last updated
- 2009-10-12
Source: ClinicalTrials.gov record NCT00993525. Inclusion in this directory is not an endorsement.